Jinyu Bio-Technology Co Ltd

According to statistics from Securities Times Data Treasure, a total of 13 companies released their 2026 semi-annual reports on August 4. Among them, Jinyu Bio posted the largest profit increase, with net profit up 72.28 percent year-on-year. Jinyu Bio achieved net profit of 104 million yuan and operating revenue of 756 million yuan, up 22.09 percent. WuXi AppTec reported net profit of 11.08 billion yuan, up 29.43 percent, on operating revenue of 28.897 billion yuan, up 38.93 percent. Companies such as Jasan Group, Sinocare, Sihui Fushi, and Wanda Bearing also recorded net profit growth, while seven companies including Jiahuan Technology and Sinodata saw net profit decline year-on-year.

Bio-Pharmaceutical announced that its subsidiary, Jinyu Baoling Biological Pharmaceutical Co., Ltd., has been approved by the Ministry of Agriculture and Rural Affairs to produce a trivalent inactivated vaccine for cattle and sheep against foot-and-mouth disease types O, A, and South African type 1, as well as a bivalent inactivated vaccine for pigs against foot-and-mouth disease types O and South African type 1, and has obtained the veterinary drug product approval number.

Jinyu Bio-technology announced that it expects net profit attributable to shareholders of the listed company for the first half of 2026 to be between 91 million yuan and 109 million yuan, representing a year-on-year increase of 50.60% to 80.39%. The profit growth was mainly driven by multiple factors, including substantial growth in the ruminant and pet animal health businesses, the emergence of synergies from industrial mergers and acquisitions, cost and expense optimization propelled by digital and lean management, and the launch of new products. The company's net profit for the first quarter was 81 million yuan, implying an expected quarter-on-quarter decline of 64% to 87% in net profit for the second quarter.